Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

NCT ID: NCT06360627

Last Updated: 2024-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-20

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation Exposure Lung Embolism Lung Cancer Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Dose

Standard Low Dose CT

Group Type OTHER

Computed Tomography

Intervention Type RADIATION

Computed Tomography CHEST

Ultra Low Dose

Ultra Low Dose CT

Group Type OTHER

Computed Tomography

Intervention Type RADIATION

Computed Tomography CHEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed Tomography

Computed Tomography CHEST

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CT SCAN for pulmonary nodule detection/follow up
* CT SCAN for pneumonia detection/follow up

Exclusion Criteria

* under 18
* BMI over 30
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich - Diagnostic Radiology

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Frauenfelder, PD MD

Role: primary

0041442551111

Marga Rominger, Prof MD

Role: backup

0041442551111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022_D0008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thoracoabdominal Arortic CTA Study
NCT02291718 COMPLETED PHASE4
Dose Reduction in Thoracic CT
NCT00188461 COMPLETED PHASE1